Consumers don’t know about or trust personalized medicine

In a nationally representative survey published in Personalized Medicine, we found that only 27 percent of respondents had heard of personalized medicine. In addition, we revealed that most (84 percent) would seek a second opinion or want a specific cancer therapy even if genetic testing indicated they are not candidates for that therapy. These results indicate that genetic information may not be used by patients to guide their healthcare decisions and that educational efforts will need to address these challenges.


Consumer familiarity, perspectives and expected value of personalized medicine with a focus on applications in oncology